BRPI0515319A - análogos de quinolona - Google Patents

análogos de quinolona

Info

Publication number
BRPI0515319A
BRPI0515319A BRPI0515319-0A BRPI0515319A BRPI0515319A BR PI0515319 A BRPI0515319 A BR PI0515319A BR PI0515319 A BRPI0515319 A BR PI0515319A BR PI0515319 A BRPI0515319 A BR PI0515319A
Authority
BR
Brazil
Prior art keywords
quinolone
analogs
quinolone analogs
present
methods
Prior art date
Application number
BRPI0515319-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Jeffrey P Whitten
Fabrice Pierre
Collin Regan
Michael Schwaebe
George Petros Yiannikouros
Michael Jung
Peter Chua
Johnny Y Nagasawa
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/149,007 external-priority patent/US7652134B2/en
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of BRPI0515319A publication Critical patent/BRPI0515319A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0515319-0A 2004-09-17 2005-09-16 análogos de quinolona BRPI0515319A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US61103004P 2004-09-17 2004-09-17
US63860304P 2004-12-22 2004-12-22
US68879605P 2005-06-09 2005-06-09
US68898605P 2005-06-09 2005-06-09
US11/149,007 US7652134B2 (en) 2004-09-17 2005-06-09 Methods for converting quinolone esters into quinolone amides
PCT/US2005/033323 WO2006034113A2 (en) 2004-09-17 2005-09-16 Quinolone analogs as cell proliferation inhibitors

Publications (1)

Publication Number Publication Date
BRPI0515319A true BRPI0515319A (pt) 2008-07-22

Family

ID=35735203

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515319-0A BRPI0515319A (pt) 2004-09-17 2005-09-16 análogos de quinolona

Country Status (11)

Country Link
US (1) US7816406B2 (enExample)
EP (1) EP1802306A2 (enExample)
JP (1) JP2008513485A (enExample)
KR (1) KR100989029B1 (enExample)
AU (1) AU2005286965B2 (enExample)
BR (1) BRPI0515319A (enExample)
CA (1) CA2580749C (enExample)
IL (1) IL181857A0 (enExample)
MX (1) MX2007003282A (enExample)
NZ (1) NZ553746A (enExample)
WO (1) WO2006034113A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1928887T3 (en) 2005-08-05 2015-03-23 Senhwa Biosciences Inc Methods for preparing quinolonanaloger
WO2007146813A2 (en) * 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Pyridinone analogs as cell proliferation inhibitors
US20100305136A1 (en) * 2006-06-08 2010-12-02 Johnny Yasuo Nagasawa Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
ES2528316T3 (es) 2006-09-01 2015-02-06 Senhwa Biosciences, Inc. Moduladores de la serina-treonina proteína quinasa y de PARP
CN101801190A (zh) * 2007-06-22 2010-08-11 赛林药物股份有限公司 治疗异常细胞增殖性疾病的方法
US20080318939A1 (en) * 2007-06-22 2008-12-25 Whitten Jeffrey P Methods for treating ophthalmic disorders
US7910600B2 (en) * 2007-08-31 2011-03-22 Cylene Pharmaceuticals, Inc. Therapeutic kinase modulators
NZ583878A (en) 2007-09-14 2012-10-26 Vertex Pharma Modulators of ABC transporter and cystic fibrosis transmembrane conductance regulator (CFTR)
PL2214491T3 (pl) * 2007-10-05 2016-11-30 Analogi chinolonów i związane z nimi sposoby
WO2011031745A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
RU2435758C1 (ru) * 2010-07-19 2011-12-10 Государственное образовательное учреждение высшего профессионального образования Волгоградский государственный технический университет (ВолгГТУ) Способ получения этилового эфира 3-оксо-3-(2,6-дихлорпиридин-3-ил) пропановой кислоты
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
BR112016026150B1 (pt) 2014-05-09 2019-11-05 Pimera Inc compostos carboxílicos e seu uso na preparação de medicamentos ou composições farmacêuticas para tratar câncer
WO2016137471A1 (en) * 2015-02-26 2016-09-01 Nantpharma, Llc Method for enhanced heparin quality
US10857156B2 (en) 2015-11-20 2020-12-08 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
US9957282B2 (en) 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
JP2018537486A (ja) * 2015-12-14 2018-12-20 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形
EP3601286A4 (en) 2017-03-28 2020-09-23 Pimera, Inc. NEW CRYSTALLINE FORMS OF A POL1 INHIBITOR
KR20200131251A (ko) 2018-02-15 2020-11-23 센화 바이오사이언시즈 인코포레이티드 퀴놀론 유사체 및 이의 염, 조성물, 및 이들의 사용 방법
JP2020189888A (ja) * 2020-08-28 2020-11-26 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形
WO2025114459A1 (en) * 2023-11-28 2025-06-05 Genome Therapeutics Ltd Tetracyclic compounds for use in antibody-drug conjugates for the treatment of cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2808070A1 (de) * 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
DE3267485D1 (en) * 1981-02-18 1986-01-02 Nippon Shinyaku Co Ltd Substituted carboxylic acid derivatives
ZA852769B (en) * 1984-04-26 1985-11-27 Abbott Lab Benzothiazolo-quinoline antibacterial compounds
US4528285A (en) * 1984-04-26 1985-07-09 Abbott Laboratories Methylenedioxy quino-benzothiazine derivatives
ZA852802B (en) * 1984-04-26 1985-11-27 Abbott Lab Benzoxazolo-quinoline antibacterial compounds
WO1989012055A1 (fr) 1988-06-08 1989-12-14 Kyorin Pharmaceutical Co., Ltd. Agent antitumoral
US4959363A (en) * 1989-06-23 1990-09-25 Sterling Drug Inc. Quinolonecarboxamide compounds, their preparation and use as antivirals.
IE912902A1 (en) 1990-08-24 1992-02-26 Abbott Lab Quinbenzoxazine, quinobenzothiazine, and pyrido-acridine¹antineoplastic agents
JPH04117388A (ja) * 1990-09-07 1992-04-17 Hokuriku Seiyaku Co Ltd チアゾロキノリン―4―カルボン酸誘導体
US5646163A (en) * 1992-10-30 1997-07-08 The Procter & Gamble Company Quinolone 5-(N-heterosubstituted amino) antimicrobials
GB9402275D0 (en) * 1994-02-07 1994-03-30 Fujisawa Pharmaceutical Co Quinoline derivatives
US6559145B2 (en) * 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6699989B1 (en) 2000-08-28 2004-03-02 B. Vithal Shetty Antiviral and antimicrobial guanidine or biguanidine derivatives
JP2004515548A (ja) * 2000-12-14 2004-05-27 ザ プロクター アンド ギャンブル カンパニー 抗微生物キノロン
US6821969B2 (en) * 2001-02-13 2004-11-23 Pharmacia & Upjohn Company Thioxazinoquinolones as antiviral agents
US6900224B2 (en) 2002-07-31 2005-05-31 The Procter & Gamble Company Antimicrobial quinolones, their compositions and uses
KR100944600B1 (ko) * 2003-04-07 2010-02-25 사일린 파마슈티칼스, 인크 치환된 퀴노벤족사진 유사체
ES2358267T3 (es) * 2004-03-15 2011-05-09 Sunesis Pharmaceuticals, Inc. Composición farmacéutica que comprende sns-595 y sus usos.

Also Published As

Publication number Publication date
CA2580749C (en) 2014-01-28
WO2006034113A2 (en) 2006-03-30
US20060074089A1 (en) 2006-04-06
AU2005286965A1 (en) 2006-03-30
WO2006034113A3 (en) 2006-08-24
KR20070085264A (ko) 2007-08-27
IL181857A0 (en) 2007-07-04
KR100989029B1 (ko) 2010-10-25
AU2005286965B2 (en) 2009-10-22
US7816406B2 (en) 2010-10-19
NZ553746A (en) 2010-06-25
CA2580749A1 (en) 2006-03-30
JP2008513485A (ja) 2008-05-01
EP1802306A2 (en) 2007-07-04
MX2007003282A (es) 2007-10-16

Similar Documents

Publication Publication Date Title
BRPI0515319A (pt) análogos de quinolona
GB2453058A (en) Kinase antagonists
BR112012008385A2 (pt) inibidores de p13 cinase e uso dos mesmos.
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
ECSP088543A (es) Anticuerpos anti-ox40l y métodos que los utilizan
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
MX391408B (es) Inhibidores de biaril meta-pirimidina de cinasas.
CL2010001538A1 (es) Compuestos derivados de pirazolo-quinazolina sustituidos, moduladores de la actividad de las proteinas quinasas; composicion farmaceutica; y su uso para el tratamiento del cancer, o un trastorno proliferativo celular.
BRPI0710521A2 (pt) quinazolinas para inibição de pdk1
DK1934174T3 (da) Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme
UA95768C2 (ru) Антагонисты мускариновых рецепторов ацетилхолина
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
CR9786A (es) Compuestos de bencimidazol-tiofeno
ATE528989T1 (de) Kristalline feste rasagilin-base
EA200701192A1 (ru) Антагонисты toll-подобного рецептора 3, способы их получения и применение
NO20072179L (no) Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer
IL176142A (en) Processes for preparing montelukast sodium
ATE497492T1 (de) Reinigung von montelukast
GT200600148A (es) Metodos para el tratamiento y la prevencion de fibrosis
ECSP088743A (es) Anticuerpos para egfl7 y métodos para su uso
SV2006002232A (es) Inhibidores bace ref. x-16940
TW200731974A (en) Transdermal system for verenicline
WO2007146813A3 (en) Pyridinone analogs as cell proliferation inhibitors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.